AURA
Aura Biosciences, Inc.
$7.00
+0.16
(+2.34%)
Mkt Cap
449.40M
Volume
593,731
52W Range
4.73-9.535
Sector
Healthcare
Beta
0.40
EPS (TTM)
-1.77
P/E Ratio
-3.10
Revenue (TTM)
0
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (106.19M) | (86.92M) | (76.41M) | (58.76M) | (35.25M) | (22.21M) | (24.20M) |
| EPS | -1.76 | -1.75 | -1.93 | -1.96 | -1.58 | -1.03 | -0.01 |
| Free Cash Flow | (85.19M) | (81.06M) | (64.56M) | (55.70M) | (34.53M) | (25.09M) | (22.89M) |
| FCF / Share | -1.41 | -1.63 | -1.63 | -1.86 | -1.18 | -0.86 | -0.01 |
| Operating CF | (84.74M) | (79.81M) | (63.85M) | (54.60M) | (32.41M) | (24.32M) | (20.67M) |
| Total Assets | 169.43M | 182.50M | 255.07M | 223.94M | 160.03M | 22.10M | 37.05M |
| Total Debt | 17.38M | 18.77M | 19.56M | 20.86M | 975,000 | 15,000 | 49,000 |
| Cash & Equiv | 59.52M | 31.69M | 41.06M | 121.58M | 149.06M | 17.39M | 32.47M |
| Book Value | 136.91M | 151.97M | 225.85M | 195.58M | 152.31M | 19.36M | 30.76M |
| Return on Equity | -0.78 | -0.57 | -0.34 | -0.30 | -0.23 | -1.15 | -0.79 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (33.69M) | (25.56M) | (26.13M) | (27.02M) | (27.48M) | (25.83M) | (21.04M) | (20.34M) | (19.71M) | (22.13M) | (18.51M) | (18.30M) |
| EPS | -0.50 | -0.40 | -0.40 | -0.47 | -0.55 | -0.52 | -0.42 | -0.41 | -0.40 | -0.50 | -0.48 | -0.48 |
| Free Cash Flow | (30.00M) | (20.64M) | (20.19M) | (20.81M) | (23.54M) | (24.25M) | (15.61M) | (16.65M) | (24.54M) | (17.70M) | (15.49M) | (14.84M) |
| FCF / Share | -0.44 | -0.34 | -0.31 | -0.36 | -0.47 | -0.49 | -0.31 | -0.34 | -0.50 | -0.40 | -0.41 | -0.39 |
| Operating CF | (29.89M) | (20.47M) | (20.14M) | (20.77M) | (23.36M) | (23.95M) | (15.27M) | (16.13M) | (24.45M) | (17.39M) | (15.40M) | (14.64M) |
| Total Assets | 137.68M | 169.43M | 190.02M | 204.40M | 155.40M | 182.50M | 205.34M | 218.28M | 235.03M | 255.07M | 179.77M | 192.74M |
| Total Debt | 16.99M | 17.38M | 17.75M | 18.11M | 18.44M | 18.77M | 19.08M | 19.03M | 19.32M | 19.56M | 20.19M | 20.41M |
| Cash & Equiv | 84.79M | 59.52M | 47.55M | 107.37M | 38.23M | 31.69M | 25.41M | 30.07M | 26.28M | 41.06M | 55.58M | 47.73M |
| Book Value | 107.25M | 136.91M | 156.67M | 174.63M | 127.97M | 151.97M | 174.67M | 191.45M | 208.78M | 225.85M | 151.72M | 166.44M |
| Return on Equity | -0.31 | -0.19 | -0.17 | -0.15 | -0.21 | -0.17 | -0.12 | -0.11 | -0.09 | -0.10 | -0.12 | -0.11 |
AURA News
Aura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directors
Auranova and Kenorland Announce Large Intrusion-Related Gold Discovery at the South Uchi Project, Ontario
Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma
Aura Biosciences Gears Up for Bel-Sar Filing as Pivotal Eye Cancer Trial Advances
Aura Biosciences Highlights Bel-Sar Eye Cancer Strategy, Mid-Year Bladder Data
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Aura Biosciences to Participate in Upcoming Investor Conferences
Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights
AMG Reports Better than Expected First Quarter 2026 Results
Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares